ruxolitinib-jak-janus-tyrosine-kinase-inhibitor-myelofibrosis-COMFORT

Ruxolitinib is a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, Aproved for therapy, in patients with myelofibrosis.

Ruxolitinib is a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, Aproved for therapy, in patients with myelofibrosis.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s